October 27th, 2014
Selections from Richard Lehman’s Literature Review: October 27th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include behavioral counseling for those with CV risk factors, long-term outcomes after stenting vs. endarterectomy for treatment of symptomatic carotid stenosis, and more.
February 25th, 2011
FDA Approves Azilsartan Medoxomil (Edarbi) for High Blood Pressure
Larry Husten, PHD
The FDA has approved azilsartan medoxomil (Edarbi, Takeda) for the treatment of high blood pressure. The new angiotensin II receptor blocker (ARB) will be available in 80 mg and 40 mg doses. The recommended dose is 80 mg once daily. The 40 mg dose is used in combination with a diuretic. The FDA said that, in clinical studies, […]
NEJM Journal Watch — Recent Cardiology Articles- Strategies and Criteria for the Diagnosis and Management of Myocarditis
- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?